Latest Chronic myelogenous leukemia Stories

New method allows faster, more efficient screening for improved diagnosticsInappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.Now, UCLA researchers from the Crump Institute for...

Patients with rare type of leukemia now have another treatment option SILVER SPRING, Md., Oct. 28 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality. (Logo:...

SUNNYVALE, Calif., Oct. 7 /PRNewswire/ -- Cepheid today announced an exclusive collaboration with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens from patients diagnosed with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Together with other lab tests, monitoring levels of BCR-ABL transcripts in Ph+ CML patients will aid in patient management. The collaboration reflects the commitment shared by...

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis's Gleevec and Tasigna and Bristol-Myers Squibb's Sprycel) and chronic lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche's Rituxan and Cephalon's Treanda) until 2015, when patent and orphan-drug exclusivities...

PHILADELPHIA, Aug. 25 /PRNewswire/ -- In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia. The event marks the 50th anniversary of the discovery of the first genetic abnormality associated with cancer, and the first to lead to a targeted therapy for cancer. The symposium...

COLUMBUS, Ohio, Aug. 24 /PRNewswire/ -- Today, leukemia patients who have struggled with cancer therapy resistance and intolerance will now have more options thanks to targeted drug therapy. Such new treatment options are due, in part, to a rapid increase in journal and patent publications following the discovery of Gleevec, as reported by Chemical Abstracts Service (CAS), the world's authority for chemical information. Since President Clinton announced that the draft sequence of the human...

Although the use of ovarian tissue cryopreservation and transplantation has lead to 13 live births in women with lymphoma or solid tumors, this method of fertility preservation may be unsafe for patients with leukemia, according to a recent study published online in Blood, the journal of the American Society of Hematology. The method involves removing and freezing ovarian tissue before the patient undergoes aggressive chemotherapy and radiotherapy, and then reimplanting the tissue once the...

Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).Results are published in Clinical Cancer Research, a journal of the American Association for Cancer Research.Imatinib, currently sold as Gleevec by Novartis, revolutionized the treatment of leukemia when it was approved in 2001. Yet imatinib comes with its own set of problems, chiefly resistance. Although...

WHITE PLAINS, N.Y., July 26 /PRNewswire/ -- Kareem Abdul-Jabbar, basketball legend and the NBA's all-time leading scorer, is asking his supporters to join him in taking a shot at beating cancer by joining his team - Team Kareem. In 2009, after Kareem's diagnosis with Philadelphia chromosome-positive chronic myeloid leukemia, (Ph+ CML), a slow progressing type of blood cancer(1), he initiated a CML education program with Novartis Oncology to show people that they are not alone in fighting...

WHITE PLAINS, N.Y., July 12 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new grants through its prestigious Marshall A. Lichtman Specialized Center of Research (SCOR) research initiative, bringing the program's total funding to $210.5 million since its inception in 2000. Both recipients have long-time connections to LLS. They are John C. Byrd, M.D., Associate Director for Translational Research, The Ohio State University Comprehensive Cancer...